Navigation Links
Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients
Date:4/23/2009

thout anemia (hemoglobin did not decrease to less than 10 g/dL). Anemia is a known adverse event with combination therapy for hepatitis C and this association with higher SVR has been seen in other clinical studies with peginterferon and ribavirin, including the IDEAL study.(4) Boceprevir is associated with about a 1 g/dL incremental decrease in hemoglobin. In the HCV SPRINT-1 study, anemia occurred in approximately half of the patients in the boceprevir arms and over a third of patients in the control arm. Erythropoietin (EPO) supplementation was allowed in the study at the discretion of the investigator and was used by 26 percent of patients in the control arm and 39-51 percent of patients in the boceprevir arms with standard-dose REBETOL.

Safety data from the study showed that the most common adverse events reported in the boceprevir arms were fatigue, anemia, nausea and headache. The incidence of skin adverse events (rash or pruritus) observed in the boceprevir arms was similar to that seen in the PEGINTRON and REBETOL control arm.

Treatment discontinuations due to adverse events in Part I of the study were between 9 and 19 percent for patients in the boceprevir arms, compared to 8 percent for the control arm. Treatment discontinuations for boceprevir patients due to viral breakthrough were fewer in the 28- and 48-week lead-in arms (4 and 5 percent, respectively) compared to the no lead-in arms (7 and 12 percent, respectively).

SCH 900518 (Next-Generation HCV Protease Inhibitor) Data at EASL

Researchers at EASL also presented early phase clinical data for SCH 900518, Schering-Plough's investigational next-generation HCV protease inhibitor.(5) This proof-of-concept study explored the safety and antiviral activity of two different dosing regimens for SCH 900518 administered as monotherapy and in combination therapy with PEGINTRON with or without ritonavir in treatment-naive and treatmen
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
2. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
3. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
4. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
5. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
6. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
7. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
8. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
9. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
10. The Anatomy of Clinical Trials: Greys Season Finale Leaves Public in the Dark About the Myths and Realities
11. Final Results of the CellCept(R) Spare the Nephron (STN) Study Show Maintenance Therapy is Associated with Improved Renal Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Mettler-Toledo International Inc. (NYSE: MTD ) today announced ... highlights: , Sales in local currency increased ... Reported sales decreased 4% as currency reduced sales growth ... per diluted share as reported (EPS) were $2.73, compared ... $2.80 , an increase of 9% over the ...
(Date:7/30/2015)... , July 30, 2015 IRIDEX Corporation (NASDAQ: ... its second quarter 2015 financial results after the market ... conjunction with the release, the Company will host a ... p.m. Eastern Time on Thursday, August 6, ... and other business developments. Interested parties may ...
(Date:7/30/2015)... 30, 2015  Tandem Diabetes Care®, Inc. (NASDAQ: ... manufacturer of the t:slim® and t:flex™ Insulin Pumps, ... Development Agreements with Dexcom, Inc. to allow the ... the Dexcom G5 and G6 continuous glucose monitoring ... pump platform with Dexcom,s future CGM systems is ...
Breaking Medicine Technology:Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3
... and Company (NYSE: LLY ) announced that it ... (PAF). The donation will enable expansion of the foundation,s patient ... in support of a new fund for patients with nonsquamous ... lung cancer.   PAF is a national, non-profit ...
... July 13, 2011 Reportlinker.com announces that ... in its catalogue: Pharmaceutical ... http://www.reportlinker.com/p0572968/Pharmaceutical-Wholesale-and-Distribution-Industry-World-Outlook-2011-2021.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Wholesali ... affect those activities? How ...
Cached Medicine Technology:Lilly Donation to Patient Advocate Foundation Expands Services and Access for Patients With Most Common Form of Lung Cancer 2Lilly Donation to Patient Advocate Foundation Expands Services and Access for Patients With Most Common Form of Lung Cancer 3Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 2Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 3Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 4Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 5Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 6Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 7Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 8Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 9Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 10Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 11Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 12Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 13
(Date:8/1/2015)... ... ... Tina Wilcoxson, owner of Freeport Maine’s Royal River Natural Foods, was named one ... Federation, the largest retail trade association in the world, for her “advocacy and engagement” ... named as such. According to the NRF’s website, Retail Champions are “Main Street business ...
(Date:8/1/2015)... CT (PRWEB) , ... August 01, 2015 , ... ... Point Partners I, L.P. (“GPP”) portfolio company has acquired Premier Physical Therapy & ... it into its portfolio of state-of-the-art clinics. , “Our acquisition of Premier Physical ...
(Date:8/1/2015)... ... ... Lume Wellness creators Alex, Robert, and Sam have announced update 3.0.1 to this ... The app is designed to track various metrics of wellness, including physical activity, diet, ... and use this information for positive behavior modification. Lume Wellness keeps track of both ...
(Date:8/1/2015)... ... 2015 , ... “ reTXT ” was featured on NewsWatch as part of ... the market for iOS, Android, and Windows. Joe Toohey, the host of AppWatch and ... edit and delete any message including ones already sent. , While text messaging has ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... High Times magazine. What are the STASH awards? The Significant Technological Achievements ... by the cannabis-cultivation community as well as tried-and-true products that have stood the ...
Breaking Medicine News(10 mins):Health News:Local Retail Advocate Wins National Recognition 2Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2Health News:Lume Wellness Launches Health and Fitness Tracker iPhone App 2Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2
... tablets such as pain killers are packaged today in ... some form of desiccant to protect the contents against ... the contents from rattling around. , However, such caps ... two hands to manipulate. Customers and,suppliers of vitamin pills ...
... an army of plant viruses to their cause, materials ... (NIST) have identified a small biomolecule that binds specifically ... bodythe calcium compound that is the basic building block ... the new molecule can be a highly discriminating probe ...
... American Tradition -- What,s the Problem?, ... Seniors Ask, WASHINGTON, ... the sight of seniors attending a,seminar about Medicare Advantage-Part D, asking questions, and ... some federal regulators,get their way., A proposed prohibition on free meals is ...
... ... Troops, BOSTON, July ... the most underserved and,at-risk groups in our country, today announced the launch ... those soldiers,who have been wounded in conflict in the Middle East and ...
... Hot Water & Healthy Living, reviews scientific findings about warm-water ... ... For those who have,wondered how warm water makes them feel so good, ... Swimming Pool Foundation,(NSPF), "Hot Water & Healthy Living" provides a thorough review ...
... ... Care, BREA, ... owners are recalculating their,household budgets. The average pet owner typically budgets for ... as,preventive health checks and vaccinations. However, most assume that their,pet,s youth or ...
Cached Medicine News:Health News:Integrated tube cap design simplifies access to medication 2Health News:Toothpick: New molecular tag IDs bone and tooth minerals 2Health News:Proposed Medicare Regulations Threaten to End Millions of Free Meals Offered to Seniors During Education Seminars 2Health News:Purple Dog Tag Launches; Provides Hope and Healing to Thousands of US Servicemen & Veterans 2Health News:New Book Reveals Warm Water Benefits for Heart, Lungs and Mind 2Health News:Veterinary Pet Insurance Reports Pet Emergencies a Costly Reality 2Health News:Veterinary Pet Insurance Reports Pet Emergencies a Costly Reality 3Health News:Veterinary Pet Insurance Reports Pet Emergencies a Costly Reality 4
Amylase (EPS-G7, kinetics), Wavelength: 405 nm. Linear range; 5-1500 IU/L....
g-GT Liquid Reagent (Kinetic Method). Wavelength: 405 nm. Linear range: 0-200 U/mL. Prepare Working Reagent in the ratio of 5 parts R1 to 1 part of R2, (i.e., 50 mL R1 and 10 mL R2)....
Intended for the quantitative determination of calcium in serum. Endpoint Reaction. Reaction complete within one minute, color developed is stable for 30 minutes. Wavelength: 570 nm. Linearity: 16 mg...
... for the quantitative determination of ... or plasma. Two vials, dry ... must be purchased separately for ... reaction. Wavelength: 340 nm. Linearity: ...
Medicine Products: